NextPharma Technologies Awarded GlaxoSmithKline Award for Excellent Service and Delivery
London, UK – 20th July 2006
NextPharma Technologies - a leading provider of product development and manufacturing outsourcing services to the biotech and pharmaceutical industry, is delighted to announce that its site in Bielefeld Germany has received from GlaxoSmithKline (GSK) Consumer Healthcare Supply Europe the 2005 Excellent Service and Delivery Performance award.
GSK presented this Award to NextPharma in recognition of its continuous delivery of measurable Key Performance Indicators.
“At NextPharma we work hand in hand with our customers to become an integral part of their supply chain. We pride ourselves on providing service excellence and I am proud of the achievement of our whole Bielefeld team commented Bill Wedlake, CEO, NextPharma Technologies. ‘Our strategy of focusing on solving our customers’ problems across the supply chain, from product development through manufacturing to distribution, ensures that we are becoming our customers’ outsourcing partner of choice”
About NextPharma
NextPharma Technologies is a leading independent supplier in the fast growing pharmaceutical and biotech product development, clinical trials supplies, manufacturing and logistics outsourcing sector. It has five product development, eight manufacturing and five logistics facilities based in Austria, Belgium, France, Germany and Switzerland employing over 1,200 people and has a customer base which includes many of the world’s leading pharmaceutical, specialty pharma and biotech companies. NextPharma’s principal shareholder is Credit Suisse First Boston Private Equity.
NextPharma is also the winner of the Frost & Sullivan 2006 Growth Strategy Leadership Award for the European Pharmaceutical Contract Manufacturing for its demonstration of exceptional growth strategy within their industry.
Contact:
Franck Latrille
Chief Executive Officer
NextPharma Technologies Holding Limited
Tel.: +44 (0) 1483 479 120
Notes to Editors:
About NextPharma
NextPharma Technologies, headquartered in the UK and founded in 2000, is world class provider of product development, contract manufacturing and distribution outsourcing services to the pharmaceutical, specialty pharmaceutical, generics and biotech industry.
It offers a broad range of services from early phase product development, through clinical trials supplies to high volume commercial manufacturing. NextPharma is a world leader in lyophilization, sterile fill-finish and pellet technologies and in specialist product manufacturing including cytotoxics, hormones, penicillins, cephalosporins and controlled substances. Its sterile development and production offers a full range of drug delivery technologies including pre-filled syringes, vials and ampoules.
NextPharma operates globally with seven product development centres, seven manufacturing plants and six storage and distribution sites across Europe and North America employing over 1,200 people. Across these locations NextPharma has built-up a strong track record in the development and manufacture of cytotoxics, hormones, antibiotics, pellets, sterile, solid, semi-solid, liquid and dry dosage forms, supplying customers in North America, Europe and Japan.
NextPharma has a customer base, which includes many of the world's leading pharmaceutical, specialty pharma and biotech companies.